Bayer (BAYN) Launches Large-Scale European Real-World Data Study of Darolutamide for Prostate Cancer Treatment
Demonstrating the Value of a New Drug in Real-World Clinical Practice
Bayer is conducting the ROAD observational study to evaluate the real-world clinical efficacy of its blockbuster drug, darolutamide (Nubeqa), in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Unlike controlled Phase 3 clinical trials, real-world clinical settings involve various variables, and data from these settings play a crucial role in increasing the reliability of drug prescriptions. This study is designed to comprehensively analyze treatment patterns and drug responses in actual patient populations, including older patients and those with pre-existing conditions, which were not fully covered in previous clinical trials (RCTs). Through this, Bayer aims to further solidify the clinical value of Nubeqa.
Tailored Strategies Through Refined Combination Therapy
This study will observe a total of 1,600 patients, divided into a doublet therapy cohort (darolutamide added to androgen deprivation therapy, ADT) and a triplet therapy cohort (including docetaxel chemotherapy). In clinical practice, clinicians must carefully weigh the pros and cons of adding chemotherapy based on the patient's age, metastatic sites, and comorbidities. Therefore, the direct comparative data between the two cohorts will provide valuable guidance for clinicians. This will provide the scientific basis necessary to establish personalized treatment strategies tailored to each patient's condition.
Quantitative Efficacy Validation Through Biomarker Measurement
The primary endpoint of the study is to measure the proportion of patients with prostate-specific antigen (PSA) levels below the detection limit (less than 0.2 ng/mL) one year after treatment initiation. In prostate cancer treatment, rapid and stable reduction in PSA levels is widely recognized as a key indicator for determining the patient's future prognosis. In addition, overall survival (OS) and time to castration-resistant prostate cancer (CRPC) will be closely monitored for up to four years. This study aims to demonstrate the long-term benefits of darolutamide more clearly by organically combining quantitative biomarkers and survival indicators.
Securing Real-World Data to Gain a Competitive Edge
Bayer plans to collect electronic case report form (eCRF) data from standard treatment processes without additional tests. This has the strong advantage of transparently reflecting the actual clinical setting without artificial intervention, preserving the objectivity and realism of the data. The accumulated large-scale real-world data (RWD) can be a marketing tool that allows darolutamide to outperform competing drugs and increase prescription preference. This data is also expected to be used as a key supporting document in future negotiations for insurance coverage in major European countries and revisions to global standard treatment guidelines.
Darolutamide has surpassed 1 billion euros in annual sales and is a key asset for Bayer. This Phase 4-level, large-scale RWE study (ROAD) is a strategic move to expand its dominance in the $7 billion metastatic hormone-sensitive prostate cancer (mHSPC) market. In the short term, it will accumulate real-world data from 1,600 patients to demonstrate superior toxicity control and patient compliance compared to strong competitors such as Pfizer's Xtandi and Johnson & Johnson's Erleada, thereby increasing prescription market share. In the medium to long term, it is expected to provide comparative analysis of doublet therapy and triplet therapy (including docetaxel), which will help to refine clinicians' prescription guidelines and lead to inclusion in national health insurance coverage and higher levels of recommendations (Guidelines). This trial is scheduled to begin in January 2026 and is expected to be completed in December 2029, and the large-scale real-world data obtained will be a key commercial basis to support the long-term safety and efficacy of darolutamide.
Source: ClinicalTrials.gov (api_ct)